

Center for Research and Training in the Sciences (UTSA),  
Institute for Integration of Medicine & Science (UTHSA),  
Translational Science Graduate Program, &  
UTSA UTHSA Joint Graduate Program in Biomedical Engineering  
invite you to attend

# STRECH

Seminars in Translational Research

Presents

## *Bcl-xl Protac - A Safer More Effective Antitumor Agent*

B-cell lymphoma extra large (BCL-XL) is a well validated cancer target. However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-XL inhibitors, such as ABT263, as safe and effective anticancer agents. We creatively used proteolysis-targeting chimera (PROTAC) technology to generate BCL-XL PROTACs to overcome the on-target toxicity of ABT263, resulting in a clinical drug candidate, DT2216, that has the potential to be developed as a safe first-in-class anticancer agent targeting BCL-XL



**Daohong Zhou, MD**

Pr  
Dir


Biology  
covery,  
y,

*Mays Cancer Center  
UT Health San Antonio*



Institute for Integration  
of Medicine & Science

**UTSA** Center for Research &  
Training in the Sciences



**Friday, October 21, 2022  
9:00AM - 10:00AM**

For information on participating in the  
current monthly seminar, please head to  
<https://www.utsa.edu/crts/strech/>  
or scan the QR code below.



✉ STRECH@UTHSCSA.edu  
☎ (210) 562-IIMS